Scioderm

Last updated

Scioderm
Industry Pharmaceuticals
FoundedApril 2013 (2013-04)
FoundersRobert Coull, CA, CBV
Robert Ryan, Ph.D.
Headquarters
Durham, North Carolina
ProductsSD-101 for epidermolysis bullosa (EB)
BrandsZorblisa

Scioderm, acquired by Amicus Therapeutics in 2015, was a rare disease company focused on developing a treatment for Epidermolysis Bullosa (EB), a rare genetic disease characterized by extremely fragile skin and recurrent blister formation. There are currently no approved therapies for EB. Scioderm was developing a topical treatment known as SD-101, or Zorblisa, aimed at triggering wound reduction and closure, and a reduction in body surface area coverage of blisters and lesions. [1]

Contents

Epidermolysis Bullosa, sometimes referred to as "Butterfly Skin", [2] is a rare genetic connective tissue disorder that, in all forms, results in extremely fragile skin that blisters or tears at the slightest friction or trauma. [3] EB typically manifests at birth or early childhood. [4] According to the Dystrophic Epidermolysis Bullosa Research Association of America (DEBRA), an estimated 1 out of every 20,000 live births are affected with some type of EB and the disorder occurs in every racial and ethnic group throughout the world and affects both sexes equally. [5]

In Scioderm's initial open-label Phase 2 study conducted in children with either Simplex, Recessive Dystrophic (RDEB), or Junctional EB, the application of SD-101 resulted in complete closure of 88% of target chronic lesions within one month, in addition to a 57% reduction in Body Surface Area (BSA) coverage of lesions and erosions after 3 months of daily treatment. [6] [7]

SD-101, now owned by Amicus Therapeutics, is currently in Phase 3 clinical development to evaluate Zorblisa as a therapy for the treatment of lesions and blistering associated with Epidermolysis Bullosa. [8] Zorblisa is the first drug to ever enter Phase 3 development for the treatment of EB. [1] Stem cell research for Epidermolysis Bullosa is also underway by researchers at the University of Minnesota pursuant to an open-label Phase 2 trial. [9]

In April 2013 Scioderm received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for its topical treatment, SD-101 for Epidermolysis Bullosa. [7] As a result of receiving Breakthrough therapy designation for SD-101, Scioderm was named a 2013 "Fierce Top 15" company by FierceBiotech. [10] [11] Prior to Scioderm's receipt of the FDA's Breakthrough therapy designation for SD-101, it had only been given to high-profile pharmaceutical companies such as Johnson & Johnson, Merck and Novartis. [12] In addition to Breakthrough therapy designation, Scioderm received Orphan Drug Designation from both the FDA and from the European Medicines Agency (EMA) for its EB treatment. [13]

History

Scioderm was co-founded by Robert Coull and Robert Ryan. [14] [15] [16] Coull and Ryan "acquired the asset from another firm, which had demonstrated a wound healing effect at a lower concentration of the active ingredient before the topical [treatment's] advancement was stalled by lack of funding." [16] In April 2013, the company received $16 million in Series A Financing from Morgenthaler Ventures and Technology Partners. [17]

On August 31, 2015, Amicus Therapeutics announced the acquisition of Scioderm in a deal valued at approximately $950 million based on the achievement of certain milestones. [18] [19] Amicus plans to complete the clinical development of SD-101 and to make the treatment commercially available for all EB patients as quickly as possible. [18]

Related Research Articles

<span class="mw-page-title-main">Biogen</span> Pharmaceutical company

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Sweden, and Switzerland.

<span class="mw-page-title-main">Epidermolysis bullosa</span> Rare medical conditions that result in easy blistering of the skin and mucous membranes

Epidermolysis bullosa (EB) is a group of rare medical conditions that result in easy blistering of the skin and mucous membranes. Blisters occur with minor trauma or friction and are painful. Its severity can range from mild to fatal. Inherited EB is a rare disease with a prevalence in the United States of 8.2 per million live births. Those with mild cases may not develop symptoms until they start to crawl or walk. Complications may include esophageal narrowing, squamous cell skin cancer, and the need for amputations.

<span class="mw-page-title-main">DEBRA</span> Medical research charity

DEBRA is the name of an international medical research charity dedicated to the curing of epidermolysis bullosa, with national groups in over 40 countries including in the United Kingdom and the United States.

<span class="mw-page-title-main">Sunovion</span> Pharmaceutical company

On July 1, 2023, Sunovion Pharmaceuticals Inc. became part of Sumitomo Pharma America, Inc., a science-based, technology-driven biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need spanning psychiatry and neurology, oncology, urology, women's health, rare disease, and cell and gene therapies.

<span class="mw-page-title-main">Epidermolysis bullosa dystrophica</span> Medical condition

Epidermolysis bullosa dystrophica or dystrophic EB (DEB) is an inherited disease affecting the skin and other organs.

<span class="mw-page-title-main">Genodermatosis</span> Medical condition

Genodermatosis is a hereditary skin disease with three inherited modes including single gene inheritance, multiple gene inheritance and chromosome inheritance. There are many different types of genodermatosis, the prevalence of genodermatosis ranges from 1 per 6000 people to 1 per 500,000 people. Genodermatosis has influence on the texture, color and structure of skin cuticle and connective tissue, specific lesion site and clinical manifestations on the body vary depending on the type. In the spite of the variety and complexity of genodermatosis, there are still some common methods that can help people diagnose. After diagnosis, different types of genodermatosis require different levels of therapy including interventions, nursing interventions and treatments. Among that, research of therapy for some new, complex and rare types are still in the developing stage. The impact of genodermatosis not only can be seen in body but also can be seen in all aspects of patients' life, including but not limited to psychological, family life, economic conditions and social activities. Accordingly, the patients need treatment, support and help in these areas.

Protein replacement therapy is a medical treatment that supplements or replaces a protein in patients in whom that particular protein is deficient or absent. There have been significant advances in this treatment. PRT is being tested in clinical trials with the diseases progeria and epidermolysis bullosa dystrophica as a potential treatment. For patients with epidermolysis bullosa dystrophica there have been promising results.

Junctional epidermolysis bullosa is a skin condition characterized by blister formation within the lamina lucida of the basement membrane zone.

A coma blister, or coma bullae, is a skin lesion or blister that typically arises due to pressure in an individual with impaired consciousness. They vary in size, ranging from 4 to 5 centimeters in diameter, and may appear hemorrhagic or blood filled. Coma blisters are usually found in the extremities and trunk. These types of blisters have been associated with the overdose of central nervous system (CNS) depressants especially barbiturates, but also tricyclic antidepressants, hypnotics, benzodiazepines, opiates, antipsychotics, and alcohol. However, studies have found that coma blisters are not caused by the toxicity of these drugs, but due to hypoxia and external pressure on the comatose individual's skin from being immobilized. Coma blisters have been frequently found on individuals who have overdosed on drugs, but have also been found on individuals with chronic kidney failure, hypercalcemia, diabetic ketoacidosis, and a variety of neurologic conditions. Coma blisters are more frequent in adults and less common among children as demonstrated by the few cases published in literature.

Teprotumumab, sold under the brand name Tepezza, is a medication used to treat adults with thyroid eye disease, a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to bulge outwards.

Bimagrumab (BYM338) is a human monoclonal antibody developed by Novartis to treat pathological muscle loss and weakness. It binds to and inhibits activin receptor type-2B.

<span class="mw-page-title-main">Amicus Therapeutics</span> Pharmaceutical company

Amicus Therapeutics is a public American biopharmaceutical company based in Philadelphia, PA. The company went public in 2007 under the NASDAQ trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.

<span class="mw-page-title-main">Ionis Pharmaceuticals</span> Biotechnology company

Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza (Nusinersen), Tegsedi (Inotersen), and Waylivra (Volanesorsen) and has 4 drugs in pivotal studies: tominersen for Huntington’s disease, tofersen for SOD1-ALS, AKCEA-APO(a)-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.

Adverum Biotechnologies, formerly known as Avalanche Biotechnologies, is a publicly traded clinical stage gene therapy company located in Redwood City, California. The company is targeting unmet medical needs for serious ocular and rare diseases, including wet age-related macular degeneration.

<span class="mw-page-title-main">Migalastat</span> Chemical compound

Migalastat, sold under the brand name Galafold, is a medication for the treatment of Fabry disease, a rare genetic disorder. It was developed by Amicus Therapeutics. The US Food and Drug Administration (FDA) granted it orphan drug status in 2004, and the European Commission followed in 2006. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) granted the drug a marketing approval under the name Galafold in May 2016.

Emapalumab, sold under the brand name Gamifant, is an anti-interferon-gamma (IFNγ) antibody medication used for the treatment of hemophagocytic lymphohistiocytosis (HLH), which has no cure.

<span class="mw-page-title-main">CRISPR Therapeutics</span> Swiss-American biotechnology company

CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval in December 2023.

Regenerative Medicine Advanced Therapy (RMAT) is a designation given by the Food and Drug Administration to drug candidates intended to treat serious or life-threatening conditions under the 21st Century Cures Act. A RMAT designation allows for accelerated approval based surrogate or intermediate endpoints.

Beremagene geperpavec, sold under the brand name Vyjuvek, is a gene therapy for the treatment of wounds. Beremagene geperpavec is the first approved gene therapy to use herpes-simplex virus type 1 as a vector. Beremagene geperpavec is a genetically modified herpes-simplex virus used to deliver normal copies of the COL7A1 gene to the wounds.

References

  1. 1 2 Hein, Alexandria (28 July 2015). "Family of NYC girl with skin-blistering condition sees hope in new drug". FoxNews.com.
  2. ↑ Lupkin, Sydney (22 February 2013). "People with 'Butterfly' Skin Condition Triumph Through Pain". Good Morning America.
  3. ↑ Nichols, Laura (18 March 2014). "Biopharma company Scioderm chooses Clearpath as its agency partner". PR WEEK.
  4. ↑ "About". sderm.com. Scioderm. Archived from the original on 31 August 2015. Retrieved 29 August 2015.
  5. ↑ "Understanding EB". debra.org. DEBRA. Archived from the original on 6 September 2015. Retrieved 28 August 2015.
  6. ↑ "Scioderm's Investigational New Drug (IND) Application for SD-101 for Treatment of Epidermolysis Bullosa (EB) Allowed by the FDA" (Press release). Scioderm. BioSpace. 14 February 2013.
  7. 1 2 "Scioderm's SD-101 Receives Breakthrough Therapy Designation from FDA for Treatment of Epidermolysis Bullosa" (PDF). sderm.com (Press release). Scioderm. 29 April 2013. Archived from the original (PDF) on 9 September 2015. Retrieved 28 August 2015.
  8. ↑ "DEBRA Current Research Trials". debra.org. DEBRA.
  9. ↑ "Stem Cell Transplants for Epidermolysis Bullosa". ClinicalTrials.gov. 7 February 2023.
  10. ↑ Carroll, John (24 September 2013). "Scioderm - 2013 Fierce 15". FierceBiotech.
  11. ↑ Carroll, John (24 September 2013). "FierceBiotech's 2013 Fierce 15". FierceBiotech.
  12. ↑ Carroll, John (30 April 2013). "Biotech upstart joins Big-Pharma cast on high profile 'breakthrough' stage". FierceBiotech.
  13. ↑ "Scioderm To Present Data From Phase 2b Study Of Zorblisa (SD-101) At The Debra International Congress" (PDF). sderm.com (Press release). Scioderm. 9 September 2014. Archived from the original (PDF) on 23 November 2015. Retrieved 9 September 2015.
  14. ↑ deBruyn, Jason (2 April 2014). "Scioderm close to fully developing new treatment for connective tissue disorder". Triangle Business Journal.
  15. ↑ "Life Sciences Awards - Robert Ryan". Triangle Business Journal. 23 May 2014.
  16. 1 2 Boggs, Jennifer (21 April 2014). "Scioderm seeks fast track with breakthrough drug for rare skin disorder". Bioworld Today.(subscription required)
  17. ↑ "Scioderm Closes $16 Million in Series A Financing". pehub.com (Press release). PE HUB. 26 April 2013.
  18. 1 2 "Amicus Therapeutics (FOLD) to acquire Scioderm in ~$950M deal". Streetinsider.com. 31 August 2015.
  19. ↑ Carroll, John (31 August 2015). "Amicus bags PhIII rare disease drug in $847M Scioderm buyout". FierceBiotech.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.